Agios Pharmaceuticals
AGIO
171 hedge funds and large institutions have $3.07B invested in Agios Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 60 increasing their positions, 54 reducing their positions, and 24 closing their positions.
30% more capital invested
Capital invested by funds: $2.37B → $3.07B (+$701M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
25% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 24
21% more call options, than puts
Call options by funds: $23.8M | Put options by funds: $19.6M
11% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 54
2% more funds holding
Funds holding: 167 → 171 (+4)
0.5% less ownership
Funds ownership: 95.68% → 95.18% (-0.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
+$27.4M |
| 2 |
Goldman Sachs
New York
|
+$15.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.8M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$14.3M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$35M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$19.8M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
-$19.7M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$18.1M |
| 5 |
AG
Artal Group
Luxembourg
|
-$15M |
AGIO Hedge Fund Activity: Q3 2017 in Review
171 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2017, worth a combined $3.07B — up 30% from $2.37B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new AGIO positions and 24 closed out — a net gain of 6 holders — while 60 added to existing stakes and 54 trimmed.
The largest buyer was Alkeon Capital Management, opening a new position worth an estimated $27.4M. The largest seller was Redmile Group, exiting entirely with an estimated $35M sold.
- 171 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2017, up from 167 in Q2 2017.
- Funds reported $3.07B of Agios Pharmaceuticals stock for Q3 2017, up 30% quarter-over-quarter.
- 30 funds opened new Agios Pharmaceuticals positions in Q3 2017 and 24 closed out, a net change of +6 holders.
- The largest Agios Pharmaceuticals buyer in Q3 2017 was Alkeon Capital Management, an estimated $27.4M added.
- The largest Agios Pharmaceuticals seller in Q3 2017 was Redmile Group, an estimated $35M sold.
Based on aggregated 13F filings for Q3 2017.